Search research articles
Contact Us
Filters
Showing results (91-100 of 130) with videos related to
Page
of 13
Sort By:
Clinical and Translational Science
|
February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Current Oncology (Toronto, Ont.)
|
April 26, 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement
Sandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Future Oncology (London, England)
|
March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 130) with videos related to
Sort By:
Page
of 13
Clinical and Translational Science
|
February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Current Oncology (Toronto, Ont.)
|
April 26, 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement
Sandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Geoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Cancer
|
January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Future Oncology (London, England)
|
March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial
Abdulazeez Salawu, Ben X Wang, Ming Han, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Page
of 13